Brands
Durex finds the other G-spot for early detection
MUMBAI: Who knew pleasure could be a lifesaver? This World Breast Cancer Day, Durex swapped seduction for self-care with its provocative new campaign, The Other G-Spot, proving once again that the world’s most playful brand can also be its most purposeful. The campaign redefines protection by linking the language of pleasure to the power of prevention, urging women to discover a spot that could truly save lives.
For years, pop culture has obsessed over the G-spot, that elusive zone of discovery and delight. Durex, however, has uncovered another, one where “G” stands for “gland”, the mammary glands where most breast cancers begin. And like its better-known namesake, this one too can only be found by touch, by women themselves.
At its heart, the campaign is a call to action, encouraging women to conduct self-examinations, schedule screenings and normalise conversations around early detection. The statistics are sobering, one woman in India is diagnosed with breast cancer every four minutes, yet only a small fraction know how to perform a self-check. Durex wants to change that, one confident conversation at a time.
In the digital film, a woman opens with the teasing line, “I found a new G-Spot, and I can’t wait to show you.” Viewers lean in, expecting a familiar Durex twist, and they get one, just not the kind they anticipated. The reveal? She’s referring to the life-saving self-exam spot.
The campaign cleverly blurs the line between sensuality and self-care, using curiosity to drive awareness. The message lands powerfully, self-touch isn’t just about pleasure, it’s about protection.
But The Other G-Spot isn’t just an ad, it’s an interactive movement. Durex is taking the conversation into private DMs, users who message the brand with “The Other G-Spot” receive a video tutorial guiding them through the art of self-examination, all explained in the familiar, confident Durex tone.
Reckitt South Asia regional marketing director, health Kanika Kalra said, “At Durex, we believe confidence and awareness go hand in hand. This campaign turns prevention into empowerment, encouraging women to see self-care as an act of strength and love.”
With The Other G-Spot, Durex once again pushes boundaries, and this time, they might just save lives doing it. Because real protection, as the brand reminds us, starts long before the bedroom.
Brands
Tata Sons defers decision on chairman N Chandrasekaran’s third term
Term runs till 2027, but board differences are stalling extension talks
MUMBAI: Tata Sons has deferred a decision on whether to extend the tenure of its chairman, N Chandrasekaran, injecting fresh uncertainty into the leadership timeline of India’s largest conglomerate.
The board had last year cleared a third executive term for Chandrasekaran running until February 2027, when he turned 65. However, deliberations on any further extension were put on hold this week after differences emerged during a board meeting, CNBC-TV18 reported, citing people familiar with the matter.
The pause underscores internal strains as the group pushes through an aggressive investment cycle while grappling with uneven financial returns. The Economic Times reported that Chandrasekaran himself asked for discussions on his reappointment to be deferred after some directors raised concerns about mounting losses at several newer businesses.
Those concerns were led by Tata Trusts chairman Noel Tata, the principal shareholder of Tata Sons. Other board members countered that losses were expected in early-stage, capital-intensive ventures designed to secure the group’s long-term position.
Since taking charge in 2017, following the ouster of Cyrus Mistry, Chandrasekaran has driven a phase of expansion and consolidation. Over the past five years, the tata group has nearly doubled revenue and more than tripled net profit and market capitalisation, while committing about Rs 5.5 lakh crore to investments aimed at making the conglomerate “future fit”, according to its latest annual report.
Recent numbers, however, present a more mixed picture. Tata Sons reported a 24 per cent rise in revenue to Rs 5.92 lakh crore in fiscal 2025, while net profit fell 17 per cent to Rs 28,898 crore.
In its annual report, the company said the year opened with expectations of macroeconomic stability and easing inflation. That optimism faded as uncertainty over global trade policy intensified, complicating the operating environment.
For now, the question of leadership continuity at the apex of the Tata Group remains unresolved and closely watched by investors assessing the cost and conviction behind the conglomerate’s long-term bets.
